{"prompt": "['2014-0546', 'August 7, 2017', 'Page 33 of 49', '30 days after the last dose of study drug must be reported on the Pregnancy Notification Form by', 'the investigational staff within 24 hr of their knowledge of the event. Any patient who becomes', 'pregnant during participation in this study must be promptly withdrawn from the study. These', 'patients will be asked to consent to allow their treating physician to provide Onconova with follow-', 'up information on the pregnancy itself and its outcome. Follow-up information regarding the', 'outcome of the pregnancy and any postnatal sequelae in the infant will be required.', '5.', 'REFERENCE LIST', 'Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera', 'and post-thrombocythemia myelofibrosis: a consensus statement from the international working', 'group for myelofibrosis research and treatment. Leukemia. 2008; 22:437-8', 'Chapman CM, Sun X, Roschewski M, et al. ON 01910.Na is selectively cytotoxic for chronic', 'lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition', 'and induction of oxydative stress. Clin Cancer Res. 2012; 18:1979-91.', 'Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom', 'assessment form total symptom score: prospective international assessment of an abbreviated', 'symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012; 30:4098-4103', 'Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University', 'School of Medicine (2007). ttp://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed', '2013/02/04.', 'Food & Drug Administration. Drug development and drug interactions: table of substrates,', 'inhibitors', 'and', 'inducers.', 'http://www.fda.gov/drugs/developmentapprovalprocess/', 'developmentresources/druginteractionslabeling/ucm093664.htm#PgpTransport', 'Jimeno A, Rubio-Viqueira B, Rajeshkumar NV, Chan A, Solomon A, Hidalgo M. A fine-needle', 'aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine', 'resistance in pancreatic cancer. Mol Cancer Ther. 2010; 9:311-8.', 'Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukemia', 'in adults. Br J Haematol. 1979; 43:185-90.', 'Mesa RA, Gotlib JR, Gupta V et al. Results using the modified myelofibrosis Symptom', 'Assessment Form (MFSAF v2.0) in Comfort I: a randomized, double-blind, phase III trial of', 'Jak 1/2 inhibitor ruxolitinib VS. Placebo in myelofibrosis. Poster 912; 16th Congress EHA; June', '2011', 'NCCN clinical practice guidelines in oncology (NCCN Guidelines\u2122M Myelodysplastic', 'syndromes. Version 2.2011.']['2014-0546', 'August 7, 2017', 'Page 34 of 49', 'Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern', 'Cooperative Oncology Group. Am J Clin Oncol. 1982; 5:649-55.', 'Olnes MJ, Shenoy A, Weinstein B et al. Directed therapy for patients with myelodysplastic', 'syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leukemia Res. 2012;', '36:982-9.', 'Prasad A, Park IW, Allen H, et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in', 'mantle cell lymphoma cells. Oncogene. 2009; 28:1518-28.', 'Raza A, Tycko B, Sangmin L, et al. Oral rigosertib (ON 01910.Na) treatment produces an', 'encouraging rate of transfusion independence in lower risk myelodysplastic syndrome (MDS)', 'patients; a genomic methylation profile is associated with responses. ASH 2013, New Orleans,', 'LA. Abstract #2745.', 'Reddy MV, Mallireddigari MR, Cosenza SC, et al. Design, synthesis, and biological evaluation', 'of (E)-styrylbenzylsulfones as novel anticancer agents. J Med Chem. 2008; 51: 86-100.', \"Rigosertib (ON 01910.Na) Investigator's Brochure. Edition 19, November 20, 2013.\", 'Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health', 'Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary', 'myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;', '110:1092-7.', 'Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International', 'Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and', 'European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395-8.', 'Thiele J, Kvasnicka HM, Facchetti F, Franco V, Ven der Walt J, Orazi A. et al. European', 'consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica.', '2005; 90:1128.', 'Vardiman JW, Thiele J, Arber DA, et al. The 2008 revisions of the World Health Organization', '(WHO) classification of myeloid neoplasms and acute leukemia: rationale and important', 'changes. Blood. 2009;114:937-51.']\n\n###\n\n", "completion": "END"}